MA38153B1 - Polypeptides stabilisés de facteur de croissance de type insuline - Google Patents

Polypeptides stabilisés de facteur de croissance de type insuline

Info

Publication number
MA38153B1
MA38153B1 MA38153A MA38153A MA38153B1 MA 38153 B1 MA38153 B1 MA 38153B1 MA 38153 A MA38153 A MA 38153A MA 38153 A MA38153 A MA 38153A MA 38153 B1 MA38153 B1 MA 38153B1
Authority
MA
Morocco
Prior art keywords
growth factor
factor polypeptides
stabilized insulin
polypeptides
relates
Prior art date
Application number
MA38153A
Other languages
English (en)
French (fr)
Other versions
MA38153A1 (fr
Inventor
Mara Fornaro
Thomas Huber
Mauro Zurini
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38153(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38153A1 publication Critical patent/MA38153A1/fr
Publication of MA38153B1 publication Critical patent/MA38153B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA38153A 2012-12-18 2013-12-16 Polypeptides stabilisés de facteur de croissance de type insuline MA38153B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738475P 2012-12-18 2012-12-18
PCT/IB2013/060985 WO2014097116A1 (en) 2012-12-18 2013-12-16 Stabilized insulin-like growth factor polypeptides

Publications (2)

Publication Number Publication Date
MA38153A1 MA38153A1 (fr) 2016-06-30
MA38153B1 true MA38153B1 (fr) 2018-06-29

Family

ID=50073229

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38153A MA38153B1 (fr) 2012-12-18 2013-12-16 Polypeptides stabilisés de facteur de croissance de type insuline

Country Status (36)

Country Link
US (1) US10167329B2 (cg-RX-API-DMAC7.html)
EP (2) EP3626735A1 (cg-RX-API-DMAC7.html)
JP (1) JP6499080B2 (cg-RX-API-DMAC7.html)
KR (1) KR102182523B1 (cg-RX-API-DMAC7.html)
CN (1) CN105121462B (cg-RX-API-DMAC7.html)
AP (1) AP2015008440A0 (cg-RX-API-DMAC7.html)
AU (1) AU2013365796B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015013708B1 (cg-RX-API-DMAC7.html)
CA (1) CA2894976C (cg-RX-API-DMAC7.html)
CL (1) CL2015001708A1 (cg-RX-API-DMAC7.html)
CR (2) CR20200079A (cg-RX-API-DMAC7.html)
CU (1) CU24308B1 (cg-RX-API-DMAC7.html)
CY (1) CY1122309T1 (cg-RX-API-DMAC7.html)
DK (1) DK2935320T3 (cg-RX-API-DMAC7.html)
EA (1) EA034356B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15031046A (cg-RX-API-DMAC7.html)
ES (1) ES2756330T3 (cg-RX-API-DMAC7.html)
GT (1) GT201500168A (cg-RX-API-DMAC7.html)
HR (1) HRP20191965T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047386T2 (cg-RX-API-DMAC7.html)
IL (1) IL239387A0 (cg-RX-API-DMAC7.html)
LT (1) LT2935320T (cg-RX-API-DMAC7.html)
MA (1) MA38153B1 (cg-RX-API-DMAC7.html)
MX (1) MX363021B (cg-RX-API-DMAC7.html)
MY (1) MY174820A (cg-RX-API-DMAC7.html)
NZ (1) NZ708091A (cg-RX-API-DMAC7.html)
PE (2) PE20200894A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501271A1 (cg-RX-API-DMAC7.html)
PL (1) PL2935320T3 (cg-RX-API-DMAC7.html)
PT (1) PT2935320T (cg-RX-API-DMAC7.html)
RS (1) RS59545B1 (cg-RX-API-DMAC7.html)
SA (1) SA515360603B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201503782PA (cg-RX-API-DMAC7.html)
SI (1) SI2935320T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000182A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014097116A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052123A1 (en) * 2013-10-02 2016-08-10 Novartis Ag Insulin-like growth factor mimetics for use in therapy
KR20180137487A (ko) * 2016-03-04 2018-12-27 샤이어 휴먼 지네틱 테라피즈 인크. 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3813861A4 (en) * 2018-06-27 2022-08-10 Juvena Therapeutics, Inc. HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USES
CN109053875B (zh) * 2018-08-31 2021-06-29 重庆大学 突变型igf-1、重组质粒、重组蛋白及应用
RU2711111C1 (ru) * 2018-09-05 2020-01-15 Илья Владимирович Духовлинов Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения
CN110642937B (zh) * 2019-10-11 2021-04-06 南开大学 多肽衍生物、纳米纤维及其应用
JP2023512423A (ja) 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途
EP4652282A2 (en) * 2023-11-14 2025-11-26 Cavalry Biosciences, Inc. Compositions for targeting muscle cells and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
WO2000040613A1 (en) 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
CA2594023C (en) * 2005-01-07 2015-07-14 Regeneron Pharmaceuticals, Inc. Igf-i fusion polypeptides and therapeutic uses thereof
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
MX2008015726A (es) 2006-06-09 2008-12-19 Novartis Ag Polipeptidos de factor de crecimiento de tipo insulina estabilizada.
ES2784926T3 (es) 2007-12-21 2020-10-02 Novartis Ag Vector de expresión de mamífero
HUE035240T2 (hu) 2009-04-27 2018-05-02 Novartis Ag Készítmények és eljárások az izomerõ növelésére
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
US10030063B2 (en) 2012-12-18 2018-07-24 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
EP3052123A1 (en) 2013-10-02 2016-08-10 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas

Also Published As

Publication number Publication date
US10167329B2 (en) 2019-01-01
CN105121462A (zh) 2015-12-02
PT2935320T (pt) 2019-11-15
EP2935320B1 (en) 2019-08-21
BR112015013708B1 (pt) 2022-10-18
PE20151612A1 (es) 2015-11-19
CN105121462B (zh) 2019-08-02
MY174820A (en) 2020-05-17
RS59545B1 (sr) 2019-12-31
CA2894976C (en) 2022-10-04
PE20200894A1 (es) 2020-09-08
WO2014097116A1 (en) 2014-06-26
AU2013365796B2 (en) 2017-03-30
ES2756330T3 (es) 2020-04-27
EP2935320A1 (en) 2015-10-28
EA034356B1 (ru) 2020-01-30
CU20150064A7 (es) 2016-02-29
CL2015001708A1 (es) 2015-08-28
HUE047386T2 (hu) 2020-04-28
NZ708091A (en) 2018-03-23
EP3626735A1 (en) 2020-03-25
KR102182523B1 (ko) 2020-11-25
SG11201503782PA (en) 2015-06-29
DK2935320T3 (da) 2019-11-18
PL2935320T3 (pl) 2020-03-31
SI2935320T1 (sl) 2019-12-31
SA515360603B1 (ar) 2020-07-26
BR112015013708A2 (pt) 2017-11-14
CR20150324A (es) 2015-08-10
PH12015501271B1 (en) 2015-08-24
MA38153A1 (fr) 2016-06-30
AU2013365796A1 (en) 2015-05-28
CY1122309T1 (el) 2021-01-27
KR20150095879A (ko) 2015-08-21
EA201591165A1 (ru) 2015-11-30
GT201500168A (es) 2016-01-21
AP2015008440A0 (en) 2015-05-31
JP2016501025A (ja) 2016-01-18
CR20200079A (es) 2020-03-21
CA2894976A1 (en) 2014-06-26
ECSP15031046A (es) 2019-03-29
TN2015000182A1 (en) 2016-10-03
MX2015007932A (es) 2015-10-05
PH12015501271A1 (en) 2015-08-24
HRP20191965T1 (hr) 2020-01-24
MX363021B (es) 2019-03-05
IL239387A0 (en) 2015-07-30
JP6499080B2 (ja) 2019-04-10
CU24308B1 (es) 2018-01-10
US20150329614A1 (en) 2015-11-19
LT2935320T (lt) 2019-11-11
HK1212712A1 (en) 2016-06-17

Similar Documents

Publication Publication Date Title
MA38153B1 (fr) Polypeptides stabilisés de facteur de croissance de type insuline
EA201201047A1 (ru) Способы и композиции, в которых применяют слитые полипептиды fgf 23
AU2018256635A1 (en) Methods for treating anemia
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
MX2021006856A (es) Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
MA35507B1 (fr) Protéines à double fonction pour le traitement de troubles du métabolisme
MX363096B (es) Composición farmacéutica para usarse en el tratamiento de la malnutrición en un sujeto que exhibe un trastorno de espectro de autismo (asd).
EA201190326A8 (ru) Полипептиды гормона роста и способы их получения и применения
MX2010005909A (es) Combinacion de inhibidores de fosfatasa de proteina tirosina y hormona de crecimiento humana para el tratamiento de atrofia muscular y trastornos relacionados.
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
MA44426B1 (fr) Compositions et méthodes pour diminier l'expression de tau
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
NZ751231A (en) Silk-derived protein for treating inflammation
MX2023003348A (es) Compuestos y composiciones como moduladores de señalización tlr.
WO2012156968A3 (en) Use of mesenchymal stem cells for the improvement of affective and cognitive function
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
MA38485A1 (fr) Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe
MX342313B (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
EA201690490A1 (ru) Миметики инсулиноподобного фактора роста для применения в терапии
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
NZ734252A (en) Blockers of the growth hormone receptor in disease prevention and treatment
WO2010012438A3 (en) Recombinant preparation of bromelain inhibitors and bromelain inhibitor precursor
TN2010000348A1 (en) Methods and compositions using klotho-fgf fusion polypeptides